Hyperalgesic pain states in chronic pain patients Signs and Symptoms Chronic pain
Conditions
Interventions
The effect of 150 mg dextromethorphan and 16 mg ondansetron orally (p.o.) will be compared to placebo in a three-way cross-over design. Sensory changes will be determined by Quantitative Sensory Testi
Sponsors
Individual Sponsor (Germany)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Healthy volunteers of full age 2. Subject familiarised with the experimental procedure prior to experimentation and had given written informed consent 3. At least a 50% increase of pain to pinprick stimuli and a 25% increase of pain to electrical stimuli following high-frequency electrical stimulation in a screening visit
Exclusion criteria
Exclusion criteria: 1. Skin lesions at the test and/or control site 2. Use of any medication within one day prior to study onset except contraceptives 3. Known hypersensitivity to histamine or to dextromethorphan and ondansetron and their derivates 4. Any history of allergy or drug hypersensitivity 5. Chronic use of analgesics or Central Nervous System (CNS) active drugs 6. Pregnancy or nursing 7. Any acute or chronic disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Spread of the area of dynamic allodynia and static hyperalgesia 2. Combined analgesic and anti-hyperalgesic effect to mechancial and electrical stimuli on the site of conditioning stimulation | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Anti-hyperalgesic effect to electrical and mechanical test stimuli 2. Analgesic effect to electrical and mechanical test stimuli 3. Anti-wind up | — |
Countries
Germany
Outcome results
None listed